HERV-K–specific T cells eliminate diverse HIV-1/2 and SIV primary isolates
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The genetic diversity of HIV-1 represents a major challenge in vaccine development. In this study, we establish a rationale for eliminating HIV-1-infected cells by targeting cellular immune responses against stable human endogenous retroviral (HERV) antigens. HERV DNA sequences in the human genome represent the remnants of ancient infectious retroviruses. We show that the infection of CD4+ T cells with HIV-1 resulted in transcription of the HML-2 lineage of HERV type K [HERV-K(HML-2)] and the expression of Gag and Env proteins. HERV-K(HML-2)-specific CD8+ T cells obtained from HIV-1-infected human subjects responded to HIV-1-infected cells in a Vif-dependent manner in vitro. Consistent with the proposed mode of action, a HERV-K(HML-2)-specific CD8+ T cell clone exhibited comprehensive elimination of cells infected with a panel of globally diverse HIV-1, HIV-2, and SIV isolates in vitro. We identified a second T cell response that exhibited cross-reactivity between homologous HIV-1-Pol and HERV-K(HML-2)-Pol determinants, raising the possibility that homology between HIV-1 and HERVs plays a role in shaping, and perhaps enhancing, the T cell response to HIV-1. This justifies the consideration of HERV-K(HML-2)-specific and cross-reactive T cell responses in the natural control of HIV-1 infection and for exploring HERV-K(HML-2)-targeted HIV-1 vaccines and immunotherapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, R. P., Wildschutte, J. H., Russo, C., & Coffin, J. M. (2011) · Retrovirology · doi:10.1186/1742-4690-8-90 · Cited by 439 · cited 1×
“Of particular relevance to this study is the relatively young and intact HERV-K human mouse mammary tumor virus-like type 2 (HML-2) family, which is present at an estimated 89 proviral copies per haploid genome (6).”
Insertional polymorphisms of full-length endogenous retroviruses in humans
Turner, G., Barbulescu, M., Su, M., Jensen-Seaman, M. I., Kidd, K. K., & Lenz, J. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00455-9 · Cited by 358
Tristem, M. (2000) · Journal of Virology · doi:10.1128/jvi.74.8.3715-3730.2000 · Cited by 330
Reconstitution of an Infectious Human Endogenous Retrovirus
Lee, Y. N., & Bieniasz, P. D. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030010 · Cited by 311 · cited 5×
“The nature of this function is presently unclear; however, it is intriguing, in light of the demonstration that APOBEC3F is a much more potent inhibitor of a reconstituted HERV-K(HML-2) virus than APOBEC3G (20), to note that NL4-3-Vif, while effective in degrading APOBEC3G, does not effectively degrade other APOBEC3 p…”
InfluentialDewannieux, M., Harper, F., Richaud, A., Letzelter, C., Ribet, D., Pierron, G., & Heidmann, T. (2006) · Genome Research · doi:10.1101/gr.5565706 · Cited by 309
Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans
Barbulescu, M., Turner, G., Seaman, M. I., Deinard, A. S., Kidd, K. K., & Lenz, J. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80390-x · Cited by 244 · cited 1×
“…complete open reading frames for viral proteins and, although no replication-competent HERV-K(HML-2) provirus has been identified yet, infectious HERV-K(HML-2) viruses can be reconstituted either from consensus sequences or by complementation among sequences from as few as 3 proviral loci (7–20).”
Boller, K., König, H., Sauter, M., Mueller-Lantzsch, N., Löwer, R., Löwer, J., & Kurth, R. (1993) · Virology · doi:10.1006/viro.1993.1487 · Cited by 188
Endogenous retroviruses: Endogenous retroviruses and cancer
Ruprecht, K., Mayer, J., Sauter, M., Roemer, K., & Mueller-Lantzsch, N. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8496-1 · Cited by 140
Dewannieux, M., Blaise, S., & Heidmann, T. (2005) · Journal of Virology · doi:10.1128/jvi.79.24.15573-15577.2005 · Cited by 137
T Cell Responses to Human Endogenous Retroviruses in HIV-1 Infection
Garrison, K. E., Jones, R. B., Meiklejohn, D. A., Anwar, N., Ndhlovu, L. C., Chapman, J. M., Erickson, A. L., Agrawal, A., Spotts, G., Hecht, F. M., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030165 · Cited by 131 · cited 5×
“ELISPOT assays were performed as previously described (25).”
InfluentialSelf-citation
Cited by
Pollack, R. A., Jones, R. B., Pertea, M., Bruner, K. M., Martin, A. R., Thomas, A. S., Capoferri, A. A., Beg, S. A., Huang, S.-H., Karandish, S., et al. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.03.008 · Cited by 370
“CTL recognition was assessed by CD107a expression as a measure of degranulation (Figure S7A) using previously optimized conditions (Jones et al., 2012).”
InfluentialSelf-citationHohn, O., Hanke, K., & Bannert, N. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00246 · Cited by 196
“Having an unchanging target allows HERV-specific T-cell clones from HIV-1 infected individuals to kill, in vitro at least, human CD4+ cells infected with viruses as diverse as HIV-1, HIV-2, and SIV (122).”
BackgroundHuman Endogenous Retrovirus Type K (HERV-K) Particles Package and Transmit HERV-K–Related Sequences
Contreras-Galindo, R., Kaplan, M. H., Dube, D., Gonzalez-Hernandez, M. J., Chan, S., Meng, F., Dai, M., Omenn, G. S., Gitlin, S. D., & Markovitz, D. M. (2015) · Journal of Virology · doi:10.1128/jvi.00544-15 · Cited by 64
Eradication of HIV and Cure of AIDS, Now and How?
Zhang, J., & Crumpacker, C. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00337 · Cited by 36
Metadata
- Authors
- Jones, R. B., Garrison, K. E., Mujib, S., Mihajlovic, V., Aidarus, N., Hunter, D. V., Martin, E., John, V. M., Zhan, W., Faruk, N. F., Gyenes, G., Sheppard, N. C., Priumboom-Brees, I. M., Goodwin, D. A., Chen, L., Rieger, M., Muscat-King, S., Loudon, P. T., Stanley, C., Holditch, S. J., Wong, J. C., Clayton, K., Duan, E., Song, H., Xu, Y., SenGupta, D., Tandon, R., Sacha, J. B., Brockman, M. A., Benko, E., Kovacs, C., Nixon, D. F., & Ostrowski, M. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-11-12
- Volume
- 122
- Issue
- 12
- Pages
- 4473-4489
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2106431826
- Cited by
- 91
- References
- 12
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HERV-K–specific T cells eliminate diverse HIV-1/2 and SIV primary isolates. https://app.cochat.ai/papers/10.1172/jci64560
- The paper
- Jones, R. B., Garrison, K. E., Mujib, S., Mihajlovic, V., Aidarus, N., Hunter, D. V., Martin, E., John, V. M., Zhan, W., Faruk, N. F., Gyenes, G., Sheppard, N. C., Priumboom-Brees, I. M., Goodwin, D. A., Chen, L., Rieger, M., Muscat-King, S., Loudon, P. T., Stanley, C., . . . Ostrowski, M. A. (2012). HERV-K–specific T cells eliminate diverse HIV-1/2 and SIV primary isolates. Journal of Clinical Investigation. https://doi.org/10.1172/jci64560
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.